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Abstract 18 
Background: It has been advocated that older adults should concomitantly spend 19 
less time in sedentary behaviour (SB), and engage in sufficient physical activity (PA), 20 
to reduce their risk of cardio-metabolic diseases. However, it is not clear what intensity 21 
of PA must be done to offset SB engagement. Aim: Model how cardio-metabolic 22 
profiles could change if older adults replaced an hour per day (hr·day-1) of a physical 23 
behaviour intensity with 1 hr·day-1 of another physical behaviour of a different intensity.  24 
Methods: Older adults (n=93, 60-89 years old, 55% female) wore a thigh-mounted 25 
triaxial accelerometer for seven consecutive free-living days to estimate mean daily 26 
hourly engagement in SB, Standing, Light Intensity PA (LIPA), sporadic moderate to 27 
vigorous physical activity (sMVPA, bouts <10 continuous minutes), and 10-minute 28 
MVPA (10MVPA, bouts ≥10 continuous minutes. Fasting whole blood concentration of 29 
plasma glucose, triglyceride, total cholesterol, and glycated haemoglobin (%), along 30 
with serum concentration of lipoprotein lipase (LPL), interleukin-6 (IL-6), and 31 
procollagen III N-terminal propeptide (PIIINP) were measured.  32 
Results: Isotemporal Substitution, with covariate adjustment, suggested that: total 33 
cholesterol concentration could theoretically decrease when 1 hr·day-1 of SB is 34 
replaced with Standing, when 1 hr.day-1 of LIPA is replaced with Standing, and when 35 
1 hr·day-1 of sMVPA is replaced with Standing. Triglyceride concentration theoretically 36 
decreased when 1 hr·day-1 of SB, Standing, LIPA, or sMVPA is replaced with 10MVPA. 37 
Triglyceride concentration theoretically increases when 1 hr·day-1 of 10MVPA is 38 
replaced with SB, Standing, or LIPA. No associations with time reallocation appears 39 
to exist for LPL, HbA1c, IL-6, and PIIINP.  40 
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Conclusion. The type of physical behaviour being replaced could be crucial for total 41 
cholesterol maintenance. Engagement in 10MVPA could be necessary to improve 42 
triglyceride concentration. 43 
 44 
Key Words: Accelerometer, Isotemporal, Physical Behaviour, Older Adults.  45 
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Introduction 46 
In the past, attitudes to physical activity recommendation for older adults was 47 
simply that “some physical activity is better than none” [1].  More recently, guidelines 48 
have been more detailed so that in the United Kingdom for instance, the 49 
recommendations are that older adults should engage in at least 150 minutes per 50 
week of moderate to vigorous physical activity (MVPA) through the accumulation of 51 
bouts of at least 10 minutes (10MVPA) [1]. Reaching this target is thought to reduce 52 
the risk of cardiovascular mortality by 35% [2]. However based on objective monitoring 53 
of physical behaviour within older adult cohorts, where cardiovascular disease is one 54 
of the leading causes of death [3], less than 15% of the population are thought to attain 55 
the 150 minutes per week 10MVPA target [4, 5]. With such low attainment rates for the 56 
10MVPA recommendation within older adult populations, it is pertinent to find and 57 
advocate, alternative physical behaviour interventions that could improve 58 
cardiovascular health for adults who do not or cannot attain the 10MVPA 59 
recommendation.  60 
Epidemiological studies have suggested that physical behaviour at intensities 61 
below MVPA could modulate cardiovascular disease risk factors, such as plasma 62 
triglycerides and glucose [6-8]. However, implementation of these findings by end-63 
users would require a change in their habitual physical behaviour profile that, in a 24-64 
hour day, would reduce the amount of time they could spend engaging in other 65 
physical behaviours. Ultimately, physical behaviour change is not just about the newly 66 
engaged physical behaviour but also about the physical behaviour that is being 67 
replaced, and the collective effects that the changes in these two physical behaviour 68 
intensities have on health status. Until recently, physical behaviour epidemiology had 69 
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failed to account for the time limiting impact of a 24-hour day when predicting how a 70 
change in a physical behaviour may affect health status.  71 
Isotemporal Substitution Modelling is a relatively new form of statistical analysis 72 
within PB research, first used to predict weight change in middle-aged women (25 – 73 
42 years) [9]. Since this seminal research, 80 publications have utilised ISM (PubMed, 74 
retrieved 26/02/2019). However, there is an apparent lack of studies that examine the 75 
associations between time reallocation and cardio-metabolic profile in older adult 76 
populations [10]. 77 
The adoption of isotemporal substitution modelling (ISM) [9] by physical 78 
behaviour researchers has now made it possible to determine how health status may 79 
be affected by replacing the time spent engaging in one physical behaviour intensity 80 
with another physical behaviour intensity. The growing evidence base of ISM has 81 
highlighted that as little as a 10-minute change in physical behaviour profile can affect 82 
cardio-metabolic status [11-20]. However, previous ISM studies have ‘objectively’ 83 
estimated the engagement in the physical behaviour spectrum with hip, waist, or wrist 84 
mounted accelerometers, which are arguably less accurate in terms of classifying 85 
posture and thus, cannot reliably distinguish between sedentary behaviour (SB) and 86 
standing, for instance, which have shown to have opposing effects on health status 87 
[12, 21-23]. 88 
Thus, the aim of the current cross-sectional study was to model how older 89 
adults’ cardio-metabolic endocrine profiles would change if they replaced an hour per 90 
day (1 hr·day-1) of a physical behaviour intensity with 1 hr·day-1 of another physical 91 
behaviour of a different intensity (e.g. replace SB with light intensity physical activity 92 
[LIPA]). It was hypothesised that replacing 1 hr·day-1 of physical behaviour for one of 93 
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a higher intensity (in terms of metabolic demands) would improve cardio-metabolic 94 
status and vice versa.   95 
Materials and Methods 96 
Ethical approval was granted by the Manchester Metropolitan University 97 
Exercise and Sports Science Ethics Sub-Committee (Approval Code: 03.11.14(i)). 98 
Written informed consent was provided by all participants prior to data collection. 99 
Participants were recruited from older adult community groups (e.g. Bridge clubs and 100 
Bowls clubs) within a rural, affluent, and highly educated county in England [24, 25] 101 
Older adults (≥ 60 years old) were eligible for the study if they were independently 102 
mobile (did not require walking aids), were not diabetic, had no current/past history of 103 
neurological disorders likely to limit mental/physical function at the time of the study, 104 
were not suffering from an un-treated cardiovascular disease. Ninety-three older 105 
adults (73.8 ± 6.23 years, 60 – 89 years, 55% female) were recruited between January 106 
2015 and June 2016. Participants visited the laboratory on two occasions, separated 107 
by at least seven days. 108 
 109 
First Laboratory Visit 110 
 During the first laboratory visit, participants were familiarised with the testing 111 
protocol that they would undergo during the second laboratory visit. Demographic 112 
information, such as height, weight, and current medical prescriptions were also 113 
collected. Medication use was presented in the following formats: the number of 114 
different medications prescribed for daily use, which could directly influence 115 
cardiovascular profile (Directly CVD Meds [n·day-1]), the number of different 116 
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medications prescribed for daily use, which could (in)directly influence cardiovascular 117 
profile ((In)directly CVD Meds [n·day-1]), the sum daily dosage of inflammatory, 118 
(in)directly influencing cardiovascular profile medication (CVD Meds [mg·day-1]), daily 119 
dose of blood pressure medication (BP Meds [mg·day-1]), daily dose of lipid-lowering 120 
medication (Lipid-Lowering Meds [mg·day-1]). 121 
 Participants were fitted with a thigh-mounted triaxial accelerometer (GENEActiv 122 
Original, Activinsights Ltd, Kimbolton, UK) on the dominant leg (anterior aspect, 50% 123 
of greater trochanter to femoral condyle distance) using two waterproof adhesive 124 
patches (3M Tegaderm Film, North Ryde, Australia) to be worn for seven consecutive 125 
free-living days. The full details of the accelerometer programming can be found in 126 
[26]. Briefly, an in-house developed data analysis software (the Cheshire Algorithm for 127 
Sedentarism [CAS]) [27] utilised 60 Hertz sampling frequency, 10 second epoch 128 
accelerometer data to determine participant time spent in SB (seated or reclined 129 
posture, ≤1.5 Metabolic Equivalent Tasks [METs]), Standing (upright posture, ≤1.5 130 
METs), LIPA (upright posture 1.5 – 3.0 METs), Sporadic MVPA (sMVPA, upright 131 
posture, ≥3.0 METS, for <10 consecutive minutes), and 10MVPA (upright posture, ≥3.0 132 
METS, for ≥10 consecutive minutes. Nighttime sleeping hours (i.e. daytime naps not 133 
included) was self-reported using a written sleep-diary and included within CAS 134 
analysis. Where sleeping hours was not reported, raw accelerometer data was cross-135 
referenced to identify prolonged nocturnal reclined posture. Thus, an estimate of when 136 
a participant went to bed and woke up on the monitored week was always possible. 137 
Three participants were removed from analysis for having <6 days of accelerometer 138 
data. 139 
 140 
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Second Laboratory Visit 141 
 Participants arrived at the laboratory in an overnight (>10 hours) fasted, 142 
hydrated state. Participants refrained from taking medication on the morning of the 143 
laboratory visit until the completion of a 10 mL venous blood sample donation. 144 
Hydration, medication intake and a light breakfast were then allowed immediately after 145 
said sampling. 146 
 147 
Whole Blood Cardio-Metabolic Analysis 148 
Immediately following blood donation (i.e. within 3 mins), whole blood analyses of total 149 
cholesterol, triglyceride, glucose, and glycated haemoglobin (HbA1c, sub-sample of n 150 
= 33) using three Accutrend Plus monitor devices and test strips (Roche Diagnostics 151 
Limited, Welwyn Garden City, UK) and one HemoCue 501 device and test cartridge 152 
(HemoCue, Ängelholm, Sweden), respectively, were carried out. Analyses were 153 
performed in triplets and averaged for total cholesterol, triglyceride, and glucose 154 
whereas only a single sample was analysed for HbA1c. Accutrend monitors have 155 
shown no difference in comparison to clinical laboratory methods in the measurement 156 
of total cholesterol, triglyceride, and glucose concentration [28]. Furthermore, the 157 
HemoCue 501 has shown good reliability (Coefficient of Variation [CV] <5/0%) and 158 
validity (Bland-Altman: 4.4 [95%CI -7.3, 16.2] mmol∙mol-1) compared to high 159 
performance liquid chromatography ion exchange [29]  160 
 The remainder of the whole blood sample was allowed to clot whilst placed on 161 
crushed ice in a 10 mL Serum Vacutainer (Becton Dickinson, New Jersey, USA) for 162 
less than two hours before centrifugation at 1687 G for five minutes (Z380, Hermle, 163 
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Gosheim, Germany). Serum was extracted into 1.0 mL aliquots (Eppendorf Ltd, 164 
Hamburg, Germany) and stored at -20 ºC until further analyses. 165 
Serum Cardio-Metabolic Analyses 166 
Concentration of serum lipoprotein lipase (LPL), procollagen III N-terminal 167 
propeptide (PIIINP), and interleukin-6 (IL-6) were determined using commercially 168 
available enzyme-linked immunosorbent (ELISA) assay kits (LPL: Cell Biolabs Inc., 169 
California, USA, PIIINP: Biomatik, Delaware, USA, IL-6: high-sensitivity, Bio-Techne, 170 
Minnesota, USA) with a two-fold sample dilution. Manufacturer intra-assay sample CV 171 
was 4% (<13% in-house) for LPL, <10% (6.5 – 9.6% in-house) for PIIINP, and 7.8% 172 
(7.4 – 9.2% in-house) for IL-6. A 96-well spectrophotometer (EL808, BioTek, Vermont, 173 
USA) connected to a computer running Gen5 c 1.11 software (BioTek, Vermont, USA) 174 
was used to derive protein concentration data. 175 
 176 
Statistical Analyses 177 
 178 
SPSS version 22 (IBM, New York, USA) was used for statistical modelling. 179 
Physical behaviour parameters, measured in mean hrs∙day-1 (SB, Standing, LIPA, 180 
sMVPA, and 10MVPA) and the summation of these parameters (Total PB) were used 181 
for ISM. Pearson correlation was used to assess multicollinearity between physical 182 
behaviour parameters and total PB; no adjustment to the data was made if 183 
multicollinearity was present. The largest case of collinearity was between SB and 184 
LIPA (r2=-0.69), which was below the suggested limits of collinearity (r2>0.9) [30]. To 185 
illustrate the effect on cardio-metabolic parameters with the replacement of one hour 186 
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of a physical behaviour with another, the replaced physical behaviour parameter was 187 
removed  from the linear regression model (forced entry) (i.e. replace SB model: 188 
Intercept + (ẞ1 х Standing) + (ẞ2 х LIPA) + (ẞ3 х sMVPA) + (ẞ4 х 10MVPA) + (ẞ5 х Total 189 
PB) + Covariates + Error) [30]. Significant predictors in the model illustrate that the 190 
replacement of a physical behaviour with the significant physical behaviour could have 191 
a predicted effect on the cardio-metabolic parameter. To standardise reporting of the 192 
ISM outcome, the removed physical behaviour is mentioned first. For example, ‘the 193 
replacement of one hour of SB with standing reduced total cholesterol’ means that SB 194 
engagement has been reduced by one hour and replaced with one hour of standing.  195 
ISM was performed without (Model 1) and with (Model 2) covariate adjustment 196 
(Directly CVD Meds [n·day-1], [In]directly CVD Meds [n·day-1], CVD Meds [mg·day-1], 197 
BP Meds [mg·day-1], Lipid-Lowering Meds [mg·day-1]). A covariate was included in the 198 
ISM if a forced entry linear regression model had highlighted an association between 199 
the covariate and the respective cardio-metabolic parameter in a preliminary analysis 200 
of the dataset. These covariates were chosen as they have previously been shown to 201 
influence the cardio-metabolic parameters of interest in the current study [31-34]. 202 
Cardio-metabolic data were naturally LOG transformed if they violated normal 203 
distribution (total cholesterol, triglyceride, LPL, IL-6, and PIIINP). Data are presented 204 
as beta coefficient (95% Confidence Interval [CI]) unless stated otherwise. Statistical 205 
significance was set at p≤0.05. 206 
 207 
Results 208 
 209 
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To enhance reader experience, this study features augmented reality. To 210 
access this feature, please download HP Reveal (Hewlett-Packard, California, USA) 211 
from your smart phone app store and create a free account. Search for, then follow 212 
DrDeclanRyan, scan your phone camera over the figures within this study to view the 213 
augmented reality attachments.  214 
The sample population characteristics are detailed below (Table 1). Over 50% 215 
of the sample population had lipid markers that were above international 216 
recommended thresholds (triglyceride: 56%, total cholesterol: 66%). Whilst for glucose 217 
markers, 35% of the sample population had a higher than recommended glucose 218 
concentration but no participants had an above threshold HbA1c percentage. Twenty-219 
one percent of the participants were not prescribed medication, whilst 30% and 60% 220 
of the population had been prescribed lipid-lowering and blood pressure medication, 221 
respectively. Notably, mean 10MVPA was below 10 mins·day-1 (Table 1), this was 222 
because 49 participants failed to register a single bout of 10-continuous minutes of 223 
MVPA across seven-days of monitoring. 224 
It is pertinent to note that for simplicity, only significant models are presented in 225 
the results section. The complete set of the results is displayed in the Supporting 226 
Information (S1 Table - S7 Tables). Significant ISM was present for total cholesterol 227 
and triglyceride (Figs 1 and 2) i.e. two out of a possible seven cardio-metabolic 228 
markers that were monitored. 229 
Table 1. Participant demographics for the study sample. Displayed as Mean 230 
(Standard Deviation) unless stated otherwise. 231 
Variable Pooled Population 
n 93  
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Female (%) 55 
Age (years) 73.8 (6.22) 
Height (m) 1.65 (0.08) 
Mass (kg) 75.9 (13.1) 
BMI (kg·m2) 27.9 (4.71) 
Covariates 
Directly CVD Meds (n∙day-1)† 1.17 (1.52) 
(In)directly CVD Meds (n∙day-1)‡ 1.62 (1.81) 
Inn+ (In)directly CVD Meds (mg∙day-1)¥ 157.86 (486.49) 
BP Meds (mg∙day-1) 9.81 (50.79) 
Lipid-Lowering Meds (mg∙day-1) 8.12 (16.58) 
Cardio-metabolic Parameters 
Triglyceride (mmol∙l-1) 1.77 (0.81)m 
Total Cholesterol (mmol∙l-1) 5.44 (1.39)m 
Glucose (mmol∙l-1) 5.72 (1.10)m 
HbA1c (%) 5.29 (0.31) 
LPL (pg∙mL-1) 113.02 (147.80)m 
IL-6 (pg∙mL-1) 2.72 (2.77)m 
PIIINP (pg∙mL-1) 229.21 (247.97)m 
Physical Behaviour Parameters 
SB (hrs∙day-1) 9.65 (1.33) 
Standing (hrs∙day-1) 1.09 (0.41) 
LIPA (hrs∙day-1) 1.97 (0.63) 
sMVPA (hrs∙day-1) 2.57 (0.64) 
10MVPA (hrs∙day-1) 0.08 (0.20)m 
Total PB (hrs∙day-1) 15.4 (4.77)m 
† Participants are currently prescribed an amount of medication that reduces the risk or treats CVD (i.e. 232 
statins, warfarin). ‡ Participants are currently prescribed a medication that may affect the cardiovascular system 233 
either directly or as a side effect. ¥ Participants are currently prescribed a medication that may affect the 234 
cardiovascular system either directly or as a side effect, including inflammatory medication. m Median (IR). 235 
Total Cholesterol 236 
 237 
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Without covariate adjustment, the replacement of 1 hr·day-1 of SB with standing 238 
was associated with a reduction in total cholesterol by (anti-logged data) 1.14 (95%CI 239 
1.28, 1.01) mmol∙l-1 (Fig 1). This is clinically relevant as a 0.5 mmol∙l-1 decrease in total 240 
cholesterol concentration is associated with a 17% decreased risk in coronary heart 241 
disease mortality [35]. The replacement of LIPA with standing was associated with a 242 
reduction in total cholesterol (anti-logged data, 1.25 [95%CI 1.49, 1.04] mmol∙l-1) (Fig 243 
1). Finally, the replacement of sMVPA with standing was associated with a reduction 244 
in total cholesterol by (anti-logged data) 1.15 (95%CI 1.32, 1.01) mmol∙l-1 (Fig 1). With 245 
adjustment for directly CVD medication (n∙day-1) and (in)directly CVD medication 246 
(n∙day-1), all significant models (model 1) remained significant (model 2) (Fig 1). 247 
 248 
Please insert Fig 1 here. 249 
Fig 1. Significant changes in total cholesterol concentration with the replacement of 1 hr·day-1 of PB 250 
with another. Model 1: no covariate adjustment. Model 2: adjusted for directly CVD medication (n∙day-251 
1) and (in)directly CVD medication (n∙day-1). Data points represent LOG data (from left to right): -95%CI, 252 
beta coefficient, +95%CI. p≤0.05. This figure is Augmented Reality Ready, download HP Reveal from 253 
your Smart Phone App Store to access the embedded videos. 254 
 255 
Triglyceride 256 
 257 
There were no covariates for triglyceride. Most notably, the replacement of any 258 
PB with 10MVPA was associated with a decrease in triglyceride concentration by 259 
similar amounts, as the change in triglyceride concentration fell between (anti-logged 260 
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data) 1.89 – 2.03 (95%CI range: 3.16, 1.17) mmol∙l-1 (Fig 2). On the other hand, the 261 
replacement of 10MVPA with any other PB (excluding sMVPA) was associated with an 262 
increase in triglyceride concentration by similar amounts (anti-logged data, beta 263 
coefficient range: 1.79 – 1.86 [95%CI range: 1.17, 2.94]) mmol∙l-1 (Fig 2). These results 264 
are clinically relevant as a 1.0 mmol∙l-1 increase in triglyceride concentration is 265 
associated with a 14% (95%CI 5, 28%, male) - 37% (95%CI 13, 66%, female) relative 266 
risk increase in CVD prevalence [36]. 267 
 268 
Please insert Fig 2 here. 269 
Fig 2. Significant changes in triglyceride concentration with the replacement of 1 hr·day-1 of PB with 270 
another. Model 1: no covariate adjustment. Data points represent LOG data (from left to right): -95%CI, 271 
beta coefficient, +95%CI. p≤0.05. This figure is Augmented Reality Ready, download HP Reveal from 272 
your Smart Phone App Store to access the embedded videos. 273 
 274 
Discussion 275 
 276 
The objective of this study was to mathematically model, using ISM, how a 277 
strictly older adult population (60 – 89 years) could change their cardio-metabolic 278 
profile through changes in PB engagement. It was hypothesised that substitution of 279 
SB or PA with PA of higher intensity may theoretically improve cardio-metabolic profile 280 
whilst the substitution of a higher intensity PA with a lower intensity PA or SB would 281 
theoretically worsen cardio-metabolic profile, as has been illustrated previously in 282 
young-middle and middle-older adult populations [11, 12, 14]. Indeed the hypotheses 283 
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were confirmed as the replacement of SB with standing was associated with a 284 
decrease in total cholesterol concentration and the replacement of any PB with 285 
10MVPA was associated with a decrease in triglyceride concentration. Therefore, the 286 
results of the current study suggested that using PB interventions could be a useful 287 
method for the prevention and treatment of lipid disorders, such as atherosclerosis, 288 
which when it manifests in the coronary arteries, is responsible for 44.5% of CVD 289 
deaths in UK older adults [3].  However, at face value, some of the total cholesterol 290 
results were counterintuitive as the replacement of sMVPA and LIPA with standing 291 
was, in fact, associated with a decrease in total cholesterol concentration. 292 
 293 
The Two Sides to Standing 294 
 295 
Total cholesterol is comprised of high-density lipid cholesterol (HDL-C), low-296 
density lipid cholesterol (LDL-C), and triglyceride. The theoretical reduction in total 297 
cholesterol concentration, after sMVPA and LIPA were replaced with standing in the 298 
current model, may be a product of lowered HDL-C, thereby suggesting that standing 299 
negatively affects cardio-metabolic status. Indeed, one month of detraining following 300 
a LIPA intervention in older adults (mean age 75.5±5.60 years) has been reported to 301 
decrease HDL-C concentration whilst LDL-C and triglyceride remained constant [37]. 302 
Not only did the modelled replacement of sMVPA and LIPA with standing 303 
theoretically reduce total cholesterol within the current study but a decrease in total 304 
cholesterol concentration was also associated with SB being replaced with standing. 305 
It could be postulated that standing is positively affecting lipoprotein profile in this case, 306 
possibly by reducing non HDL-C lipoproteins. This postulation is in agreement with a 307 
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previous four-day intervention study in young adults (21±2 years), which found non-308 
HDL-C concentration decreased from 2.94±0.47 to 2.65±0.48 mmol·l-1 following the 309 
replacement of six hours of SB with two hours of standing and four hours of walking, 310 
compared to a 14 hrs·day-1 of SB day [23]. Meanwhile, there was also a non-significant 311 
trend for total cholesterol to decrease from 4.20±0.67 to 3.96±0.50 mmol·l-1 (p=0.17) 312 
[23]. Although ISM can suggest an intervention, it cannot state how long an 313 
intervention can take to have a significant effect on health status. However, along with 314 
the results of Duvivier, Schaper [23], it could be suggested that the replacement of 315 
one hour of SB with standing could reduce total cholesterol if the intervention lasts 316 
longer than four days.  317 
Overall, these findings suggested that standing could affect circulating 318 
cholesterol, differentially, depending on which PB parameter it is displacing and thus 319 
facilitates the prediction of individualised outcomes for PB change interventions.  320 
 321 
Benefits of Prolonged Moderate Activity 322 
 323 
Performing longer bouts of MVPA may induce a chronic physiological effect that 324 
protects against physical inactivity, as total cholesterol concentration modelling was 325 
predicted to decrease when sMVPA, but not 10MVPA, was replaced with standing 326 
within the current study. In terms of the time frame for adaption in cholesterol profile 327 
with the introduction of physical inactivity, previous studies have varied considerably 328 
depending on what duration of MVPA bouts were being undertaken prior to physical 329 
inactivity. For example, the lipoprotein profile of trained endurance rowers took 29 330 
weeks, following the cessation of exercise (performed in bouts of MVPA ≥10 mins), to 331 
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become significantly different. Specifically, HDL-C decreased from 0.92±0.09 pre 332 
detraining to 0.81±0.11 mmol·l-1 post detraining (p<0.05, a 0.004 mmol·l-1 reduction 333 
per week) [38]. Whereas, it took only four weeks until HDL-C concentration was 334 
significantly reduced (from 1.42±0.05 to 1.34±0.05 mmol·l-1, p<0.05, a 0.02 mmol·l-1 335 
reduction per week) following the cessation of a four-month interval training 336 
intervention (performed in bouts of MVPA <10 mins, 4 × 4 mins MVPA, 3 mins rest) 337 
[39]. Despite these previous finding being reported in middle-aged adults, there are 338 
similarities in cardio-metabolic change with a reduction in MVPA when compared with 339 
the current study. It is likely that engagement in prolonged bouts of MVPA (10MVPA) 340 
would be beneficial in the preservation of long-term cholesterol profile should an older 341 
adult be temporarily forced into a physically inactive lifestyle (i.e. prolonged bedrest 342 
due to illness or injury). 343 
Furthermore, the associated reduction in fasted triglyceride concentration when 344 
any PB, including sMVPA, was replaced with 10MVPA in the current study, also 345 
strengthens the theorem that prolonged MVPA bouts would improve/maintain 346 
lipoprotein profile. In addition, the lack of association on fasted triglyceride 347 
concentration when SB was replaced for PA suggests that a focus on reducing 348 
physical inactivity is more important than SB reduction when attempting to improve 349 
triglyceride profile. Whereas the lack of effect on fasted total cholesterol when 10MVPA 350 
is replaced in the model (and improvements when SB is replaced) could suggest that 351 
SB reduction as opposed to physical inactivity reduction could be more important for 352 
total cholesterol profile improvements, possibly due to the effects on LDL-C and HDL-353 
C pathway alluded to above. However, intervention studies would be required to 354 
confirm or deny the hypotheses engendered through the present modelling exercises.  355 
 356 
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No Effect of Physical Behaviour on Lipoprotein Lipase 357 
 358 
Pre-heparin serum LPL concentration was measured within the current study 359 
and it is thought to represent whole-body LPL production and the systemic potential 360 
to hydrolyse triglycerides [40, 41]. Additionally, pre-heparin serum LPL has been 361 
shown to be inversely related to the progression of coronary artery disease in 362 
young/middle – older aged populations (Hitsumoto, Ohsawa [42]: 22 – 79 years, Rip, 363 
Nierman [43]: 45 – 79 years), highlighting that pre-heparin serum LPL is anti-364 
atherogenic. Furthermore, exercise has been shown to increase LPL within humans 365 
and rats in all age groups [44-46], thus suggesting that PA can protect against 366 
atherosclerosis through the mediation of the LPL pathway. Conversely, the results of 367 
the current modelling study suggested that the replacement of any PB may not 368 
necessarily affect serum LPL concentration. A possible explanation for these results 369 
is that pre-heparin serum LPL is representative of whole-body LPL [40, 41], in which, 370 
the expression of LPL within certain sites can portray a pro-atherogenic effect (e.g. 371 
artery wall) [47]. Therefore, the representation of both pro and anti-atherogenic LPL 372 
within pre-heparin serum LPL may cause ‘noise’ within the ISM, thus nullifying any 373 
effects on pro or anti-atherogenic LPL that may exist with PB change. Furthermore, 374 
this ‘noise’ is likely to be more pronounced in the older adult population, who already 375 
have an increased serum LPL concentration compared to middle aged adults [48] and 376 
are more likely to show progression of atherosclerosis, which has been positively 377 
associated with LPL concentration within the aorta [49]. 378 
 379 
Not Statistically Significant but Clinically Significant Results 380 
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 381 
Although the confidence interval range of some of the cardio-metabolic markers 382 
suggested no association with PB substitution, there were beta co-efficients and 383 
confidence intervals that were large enough to suggest some clinical relevance. 384 
Previous findings from Emerging Risk Factors Collaboration [50] suggested that a 1 385 
mmol·l-1 increase in fasting plasma glucose was associated with a 12% increase in 386 
hazard ratio for coronary heart disease incidents. Within the findings of the current 387 
study, replacing 10MVPA with SB had a beta-coefficient of 0.38 mmol·l-1 and an upper 388 
confidence interval limit of 2.04 mmol·l-1 (S4 Table). This may suggest that some older 389 
adults will experience adverse effects of replacing 10MVPA with SB. It could be that 390 
the design of this study may not have been sufficient to detect statistically significant 391 
associations, but it should not mean that future studies dismiss further research. 392 
   393 
Strengths and Limitations 394 
 The current study’s strength include the utilisation of a week-long thigh-395 
mounted accelerometer to accurately detect all physical behaviours including 396 
sedentary behaviour, every 60 seconds. Another strength was the fact that the 397 
accelerometers were thigh mounted which allowed for the investigation of standing; a 398 
physical behaviour which has shown mixed results in randomised cross-over trials in 399 
terms of its impact on cardio-metabolic profile during prolonged sitting [22, 23, 51, 52]. 400 
Furthermore, the physical behaviour data in our study has allowed the investigation of 401 
the importance of the 10-minute criterion for MVPA, which is a current discussion point 402 
within the UK physical activity guidelines. Finally, the utilisation of isotemporal 403 
substitution analysis is essentially mathematical modelling of potentially effective 404 
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physical behaviour change guidance, ultimately useful to both practitioners and end-405 
users, as such analyses may assist with individualising physical behaviour 406 
programmes. It is nevertheless noted that given the cross-sectional study design, the 407 
presence of reverse causality bias for instance, cannot be ruled out. In addition to this, 408 
as this study was performed on a relatively small sample, some of the analysis may 409 
have been under-powered, increasing the chance of a type II error. An 410 
unsurmountable study limitation in this cross-sectional study design, was the fact that 411 
we could not stop participants taking pre-existing medications and indeed it would 412 
have been unrealistic and unrepresentative of an older population to have only 413 
recruited older persons on zero phamaceuticals. Whilst we applied statistical 414 
adjustment to this limitation by treating medication use as a covariate, the fact that we 415 
reduced this data to the categorical level means that the precision of our adjustment 416 
was limited. Future research should conduct this modelling with longitudinal data of a 417 
larger older adult sample size. We also recommend that future studies be statistically 418 
powered to recruit samples large enough to have sufficient numbers of participants 419 
using similar drug therapies. In this way, the amount and type of medication can be 420 
recorded and thus used at the ratio/interval level, thereby improving on the quality of 421 
adjustments. 422 
 423 
Conclusion 424 
 425 
The current study added further evidence to support the 10-minute bout 426 
recommendation within the MVPA guidelines of PA for older adults, as well as 427 
highlighting that quantitative guidelines are required for reducing SB engagement in 428 
21 
 
older adults. Finally, the current study has potentially shown that a PB can have both 429 
a positive and negative effect on cardio-metabolic status (though requiring further 430 
investigation), dependent on what PB it is replacing. Thus, advocating the need for 431 
individualised interventions, where possible, that account for the participant’s habitual 432 
PB engagement, rather than a one size fits all approach. 433 
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